Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 May;23(5):598.
doi: 10.18553/jmcp.2017.23.5.598.

Letter--Prudent Formulary Management or Underutilization of the Novel P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention?

Ole Hauch  1
Affiliations
Comment

Letter--Prudent Formulary Management or Underutilization of the Novel P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention?

Ole Hauch. J Manag Care Spec Pharm. 2017 May.

Abstract

The author is a former employee of AstraZeneca and owns stock in AstraZeneca. The author reports no conflicts of interest related to the subject of this letter.

PubMed Disclaimer

Conflict of interest statement

The author is a former employee of AstraZeneca and owns stock in AstraZeneca. The author reports no conflicts of interest related to the subject of this letter.

Comment in

  • Letter--The Authors Respond.
    Kim K, DiDomenico RJ, Touchette DR, Walton SM. Kim K, et al. J Manag Care Spec Pharm. 2017 May;23(5):599-600. doi: 10.18553/jmcp.2017.23.5.599. J Manag Care Spec Pharm. 2017. PMID: 28448774 Free PMC article.

Comment on

References

    1. Kim K, Lee TA, Touchette DR, DiDomenico JR, Ardati AK, Walton SM. Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome. J Manag Care Spec Pharm. 2017:23(1):57-63. Available at: http://www.jmcp.org/doi/full/10.18553/jmcp.2017.23.1.57. - DOI - PMC - PubMed
    1. Angerås O, Hasvold P, Thuresson M, Deleskog A, ÖBraun O. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study. Scand Cardiovasc J. 2016;50(2):99-107. - PMC - PubMed
    1. Alexopoulos D, Xanthopoulou I, Deftereos S, et al. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. J Thromb Haemost. 2016;14(6):1146-54. - PubMed
    1. Beigel R, Iakobishvili Z, Shlomo N, et al. Real-world use of novel P2Y12 inhibitors in patients with acute myocardial infarction: a treatment paradox. Cardiology. 2017;136(1):21-28. - PubMed
    1. Sahlén A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37(44):3335-42. - PubMed

Substances

LinkOut - more resources